CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma
Advanced Science · 2025-02 · 12 (5)
DOI: 10.1002/advs.202412967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.12.2024. Verfasst von Yizeng Fan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immunotherapy, Autophagy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). However, whether targeting PBRM1 has the potential to enhance immunotherapy efficacy in patients with wild‐type PBRM1 and the upstream pathways that regulate PBRM1 protein stability remain unclear. Here, it is demonstrated that PBRM1 knockdown induced M1 macrophage polarization and infiltration, which enhanced the efficacy of anti‐PD‐1 immunotherapy in RCC. Meanwhile, CDC20 catalyzes K27 ubiquitination of PBRM1 and promotes its degradation via p62‐mediated selective autophagy. A bicyclic peptide (PB1‐p62) is designed and constructed to target PBRM1 and p62, thereby promoting the degradation of PBRM1. As a result, the efficacy of anti‐PD‐1 immunotherapy is enhanced, leading to improved overall survival rates in syngeneic mouse tumor models. Overall, this finding suggest the clinical application of PB1‐p62 and provide a novel approach for enhancing the effectiveness of immunotherapy in RCC patients with wild‐type PBRM1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
- Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, 710061, P. R. China.
- Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
ORCID-Profile: Lei Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fan, Y., Dan, W., Que, T., Wei, Y., Liu, B., Wang, Z., Zhang, Y., Wang, Y., Liu, T., Zhuang, Y., Li, M., Guo, C., Zeng, J., Ma, B., & Li, L. (2025). CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma. Advanced Science, 12(5). https://doi.org/10.1002/advs.202412967
Vancouver
Fan Y, Dan W, Que T, Wei Y, Liu B, Wang Z, et al. CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma. Advanced Science. 2025;12(5). doi:10.1002/advs.202412967
BibTeX
@article{Fan2025,
author = {Fan, Yizeng and Dan, Weichao and Que, Taotao and Wei, Yi and Liu, Bo and Wang, Zixi and Zhang, Yulin and Wang, Yuzhao and Liu, Tianjie and Zhuang, Yanxin and Li, Mengxing and Guo, Chendong and Zeng, Jin and Ma, Bohan and Li, Lei},
title = {CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {5},
doi = {10.1002/advs.202412967}
}
EUVIMED